In trading on Tuesday, shares of Novavax, Inc. (Symbol: NVAX) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $7.89 per share. By comparison ...

Deep-pocketed investors have adopted a bullish approach towards Novavax (NASDAQ:NVAX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

GAITHERSBURG, Md., Nov. 11, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today ...

Shares of Novavax (NVAX), a pharmaceutical company, declined over 6% following the release of its third-quarter results. Though the company reported a lower-than-expected loss and surpassed ...

Novavax, Inc. ( NASDAQ:NVAX ) investors will be delighted, with the company turning in some strong numbers with ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Novavax, Inc. (Symbol: NVAX), where a total of 61,950 contracts have traded so far ...

(RTTNews) - Novavax Inc. (NVAX) released Loss for third quarter that decreased from last year and beat the Street estimates. The company's bottom line totaled -$121.30 million, or -$0.76 per share.

Novavax (NVAX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.26 per share a year ago. These figures are ...

The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

Novavax NVAX incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1. ...

Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported quarter, the company’s earnings missed estimates by 45.60%. The Zacks ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced Nuvaxovid sales of $38.2M, which beat consensus ...